PMID- 17475518
OWN - NLM
STAT- MEDLINE
DCOM- 20070816
LR  - 20220318
IS  - 1078-5884 (Print)
IS  - 1078-5884 (Linking)
VI  - 34
IP  - 1
DP  - 2007 Jul
TI  - Association of circulating transforming growth factor beta, tumor necrosis factor 
      alpha and basic fibroblast growth factor with restenosis after transluminal 
      angioplasty.
PG  - 35-43
AB  - OBJECTIVES: To assess prospectively the early time course of Transforming Growth 
      Factor beta-1 (TGFbeta-1), basic Fibroblast Growth Factor (bFGF) and Tumor 
      Necrosis Factor alpha (TNFalpha) as possible contributors to restenosis 
      development after angioplasty. DESIGN: Prospective Study. METHODS: The levels of 
      the soluble forms of these factors in the early response to Percutaneous 
      Transluminal Angioplasty (PTA) in the arteries of the lower limb were 
      prospectively assessed. 32 patients with peripheral arterial occlusive disease 
      (PAOD), presenting with intermittent claudication (Fontaine stage IIb) were 
      scheduled for angioplasty treatment. Serum levels of TGFbeta-1, TNFalpha and bFGF 
      were assessed before intervention, 15 and 60 minutes after, 24 hours after as 
      well as 2 and 4 weeks after intervention. We compared the distribution patterns 
      between patients treated with balloon angioplasty and patients who required 
      secondary stent implantation. Endpoint was the development of restenosis within 6 
      months after interventional treatment, defined as a lumen diameter reduction of 
      more than 50% by ultrasound measurement compared to the result after PTA. 
      RESULTS: The patients who later developed restenosis had significantly higher 
      levels of TGFbeta-1 at 15 minutes, 24 hours and 2 weeks after PTA (p<0.05). 
      TNFalpha and bFGF were only detected in a few patients and no significant change 
      of serum levels was observed. CONCLUSION: The results demonstrate a possible role 
      of TGFbeta-1 in the formation of restenosis after PTA.
FAU - Wildgruber, M
AU  - Wildgruber M
AD  - Department of Vascular Surgery, Klinikum rechts der Isar, Technical University of 
      Munich, Germany.
FAU - Weiss, W
AU  - Weiss W
FAU - Berger, H
AU  - Berger H
FAU - Wolf, O
AU  - Wolf O
FAU - Eckstein, H-H
AU  - Eckstein HH
FAU - Heider, P
AU  - Heider P
LA  - eng
PT  - Journal Article
DEP - 20070502
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
RN  - 0 (Biomarkers)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Aged
MH  - Angiography
MH  - Angioplasty, Balloon/*adverse effects
MH  - Biomarkers/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fibroblast Growth Factor 2/*blood
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*blood/diagnostic imaging
MH  - Humans
MH  - Intermittent Claudication/diagnostic imaging/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Transforming Growth Factor beta/*blood
MH  - Tumor Necrosis Factor-alpha/*blood
EDAT- 2007/05/04 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/05/04 09:00
PHST- 2006/11/01 00:00 [received]
PHST- 2007/02/15 00:00 [accepted]
PHST- 2007/05/04 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/05/04 09:00 [entrez]
AID - S1078-5884(07)00148-7 [pii]
AID - 10.1016/j.ejvs.2007.02.009 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2007 Jul;34(1):35-43. doi: 10.1016/j.ejvs.2007.02.009. 
      Epub 2007 May 2.